314 NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer Article Swipe
Bérengère Salomé
,
John P. Sfakianos
,
Andrew Charap
,
Adam M. Farkas
,
Daniel Geanon
,
Geoffrey Kelly
,
Ronaldo de Real
,
Brian Lee
,
Kristin G. Beaumont
,
Sanjana Shroff
,
Ying‐Chih Wang
,
Yuanshuo Wang
,
Li Wang
,
Robert Sebra
,
Alice O. Kamphorst
,
Karl‐Johan Malmberg
,
Emanuela Marcenaro
,
Pedro Romero
,
Rachel Brody
,
Yuko Yuki
,
Maureen P. Martin
,
Mary Carrington
,
Reza Mehrazin
,
Peter Wiklund
,
Jun Zhu
,
Matthew D. Galsky
,
Nina Bhardwaj
,
Amir Horowitz
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1136/jitc-2021-sitc2021.314
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1136/jitc-2021-sitc2021.314
Background Bladder cancer is characterized by a poor prognosis, with muscle-invasive cases harboring a 34–76% 10-year recurrence-free survival rate. 1 Neoadjuvant PD-1/PD-L1 blockade strategies have recently been approved by the US Food and Drug Administration for bladder cancer treatment, yet only achieving a complete response rate of 31–37%, thereby suggesting additional mechanisms of resistance. 2 HLA-E is a known inhibitor of NKG2A+ CD8 T cells and NK cell responses. A monoclonal antibody binding to the NKG2A receptor has been developed and proven to restore CD8 T cell and NK cell responses in head and neck cancer, with ongoing clinical trials across multiple tumor indications. 3 4 We evaluated the potential role of the HLA-E/NKG2A inhibitory pathway in modulating T cell immunity in bladder cancer. Methods CyTOF was performed on CD8+ T cells from fresh bladder tumors (n=6), as well as on expanded CD8+ T cells from bladder-draining lymph nodes (n=11) and tumors (n=8). Flow cytometry (n=25) and single-cell RNA-sequencing (scRNAseq) (n=13) were performed on cells from fresh bladder tumors. Results Mechanisms of tumor escape from CD8+ T cell recognition include impairment of antigen presentation. Accordingly, we found a significant reduction of HLA class I expression on tumors. However, expression of DNAM-1-activating ligands (e.g. CD112,CD155) on bladder tumors was retained, indicating a possible role for TCR-independent activation pathways traditionally ascribed to natural killer (NK) cells. Using mass cytometry and scRNAseq, we observed that acquisition of NKG2A on tumor-derived PD-1+ CD8+ T cells promotes tissue-resident memory features alongside diminished CD28 expression and significantly weaker sensitivity to CD3/CD28-signaling. However, NKG2A+ CD8 T cells possess a proliferative advantage with enhanced expression of DNAM-1 and cytolytic machinery.Strikingly, we found that NKG2A+PD-1+ CD8 T cells are strongly activated in response to HLA class I-deficient tumors compared to their NKG2A- PD-1+ CD8 T cell counterparts. TCR-independent NK-like function by NKG2A+ CD8 T cell is partly mediated by the DNAM-1 pathway and inhibited by HLA-E. NKG2A+ CD8 T cell functions are restored upon NKG2A blockade, where efficiency positively correlates with HLA-E expression on bladder tumors. Conclusions Collectively, our data indicate that NKG2A+ CD8 T cells display a strong capacity for TCR-independent activation that enables them to circumvent bladder tumor evasion mechanisms. NKG2A+ CD8 T cells lack expression of CD28 suggesting a lower susceptibility to PD-1-mediated inhibiton. Our data suggest a need for thorough reappraisal of current protocols that assess CD8 T cell exhaustion and for strategies to restore their antitumor functions. References Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y. Bladder cancer. Nat Rev Dis Primers 2017 April 13; 3 :17022. doi: 10.1038/nrdp.2017.22. PMID: 28406148. Rouanne M, Bajorin DF, Hannan R, Galsky MD, Williams SB, Necchi A, Sharma P, Powles T. Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder. Eur Urol Oncol 2020 December; 3 (6):728–738. doi: 10.1016/j.euo.2020.06.009. Epub 2020 Nov 8. PMID: 33177001. André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK Cells. Cell 2018 December 13; 175 (7):1731–1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29. PMID: 30503213; PMCID: PMC6292840. van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer 2019 October 17; 7 (1):263. doi: 10.1186/s40425-019-0761-3. PMID: 31623687; PMCID: PMC6798508.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1136/jitc-2021-sitc2021.314
- https://jitc.bmj.com/content/jitc/9/Suppl_2/A338.full.pdf
- OA Status
- bronze
- Cited By
- 2
- References
- 5
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3214625671
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3214625671Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1136/jitc-2021-sitc2021.314Digital Object Identifier
- Title
-
314 NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancerWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-11-01Full publication date if available
- Authors
-
Bérengère Salomé, John P. Sfakianos, Andrew Charap, Adam M. Farkas, Daniel Geanon, Geoffrey Kelly, Ronaldo de Real, Brian Lee, Kristin G. Beaumont, Sanjana Shroff, Ying‐Chih Wang, Yuanshuo Wang, Li Wang, Robert Sebra, Alice O. Kamphorst, Karl‐Johan Malmberg, Emanuela Marcenaro, Pedro Romero, Rachel Brody, Yuko Yuki, Maureen P. Martin, Mary Carrington, Reza Mehrazin, Peter Wiklund, Jun Zhu, Matthew D. Galsky, Nina Bhardwaj, Amir HorowitzList of authors in order
- Landing page
-
https://doi.org/10.1136/jitc-2021-sitc2021.314Publisher landing page
- PDF URL
-
https://jitc.bmj.com/content/jitc/9/Suppl_2/A338.full.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://jitc.bmj.com/content/jitc/9/Suppl_2/A338.full.pdfDirect OA link when available
- Concepts
-
Bladder cancer, CD8, Medicine, Cytotoxic T cell, Cancer research, T cell, T-cell receptor, Flow cytometry, Cancer, Immunology, Immune system, Internal medicine, Biology, In vitro, BiochemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
2Total citation count in OpenAlex
- Citations by year (recent)
-
2023: 1, 2021: 1Per-year citation counts (last 5 years)
- References (count)
-
5Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3214625671 |
|---|---|
| doi | https://doi.org/10.1136/jitc-2021-sitc2021.314 |
| ids.doi | https://doi.org/10.1136/jitc-2021-sitc2021.314 |
| ids.mag | 3214625671 |
| ids.openalex | https://openalex.org/W3214625671 |
| fwci | 0.20644306 |
| type | article |
| title | 314 NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | A338 |
| biblio.first_page | A338 |
| topics[0].id | https://openalex.org/T11020 |
| topics[0].field.id | https://openalex.org/fields/24 |
| topics[0].field.display_name | Immunology and Microbiology |
| topics[0].score | 0.9991999864578247 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2403 |
| topics[0].subfield.display_name | Immunology |
| topics[0].display_name | Immune Cell Function and Interaction |
| topics[1].id | https://openalex.org/T10158 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9976000189781189 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Cancer Immunotherapy and Biomarkers |
| topics[2].id | https://openalex.org/T10458 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9958000183105469 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2746 |
| topics[2].subfield.display_name | Surgery |
| topics[2].display_name | Bladder and Urothelial Cancer Treatments |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2780352672 |
| concepts[0].level | 3 |
| concepts[0].score | 0.7136555910110474 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q504775 |
| concepts[0].display_name | Bladder cancer |
| concepts[1].id | https://openalex.org/C167672396 |
| concepts[1].level | 3 |
| concepts[1].score | 0.6312844753265381 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q417800 |
| concepts[1].display_name | CD8 |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.60052490234375 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C154317977 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5411959886550903 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q376266 |
| concepts[3].display_name | Cytotoxic T cell |
| concepts[4].id | https://openalex.org/C502942594 |
| concepts[4].level | 1 |
| concepts[4].score | 0.5347769260406494 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[4].display_name | Cancer research |
| concepts[5].id | https://openalex.org/C2776090121 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5219666361808777 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q193529 |
| concepts[5].display_name | T cell |
| concepts[6].id | https://openalex.org/C19317047 |
| concepts[6].level | 4 |
| concepts[6].score | 0.4712282419204712 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q412037 |
| concepts[6].display_name | T-cell receptor |
| concepts[7].id | https://openalex.org/C553184892 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4605281949043274 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1141429 |
| concepts[7].display_name | Flow cytometry |
| concepts[8].id | https://openalex.org/C121608353 |
| concepts[8].level | 2 |
| concepts[8].score | 0.42054545879364014 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[8].display_name | Cancer |
| concepts[9].id | https://openalex.org/C203014093 |
| concepts[9].level | 1 |
| concepts[9].score | 0.4188340902328491 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[9].display_name | Immunology |
| concepts[10].id | https://openalex.org/C8891405 |
| concepts[10].level | 2 |
| concepts[10].score | 0.39688557386398315 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[10].display_name | Immune system |
| concepts[11].id | https://openalex.org/C126322002 |
| concepts[11].level | 1 |
| concepts[11].score | 0.21268999576568604 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[11].display_name | Internal medicine |
| concepts[12].id | https://openalex.org/C86803240 |
| concepts[12].level | 0 |
| concepts[12].score | 0.20511844754219055 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[12].display_name | Biology |
| concepts[13].id | https://openalex.org/C202751555 |
| concepts[13].level | 2 |
| concepts[13].score | 0.081968754529953 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q221681 |
| concepts[13].display_name | In vitro |
| concepts[14].id | https://openalex.org/C55493867 |
| concepts[14].level | 1 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[14].display_name | Biochemistry |
| keywords[0].id | https://openalex.org/keywords/bladder-cancer |
| keywords[0].score | 0.7136555910110474 |
| keywords[0].display_name | Bladder cancer |
| keywords[1].id | https://openalex.org/keywords/cd8 |
| keywords[1].score | 0.6312844753265381 |
| keywords[1].display_name | CD8 |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.60052490234375 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/cytotoxic-t-cell |
| keywords[3].score | 0.5411959886550903 |
| keywords[3].display_name | Cytotoxic T cell |
| keywords[4].id | https://openalex.org/keywords/cancer-research |
| keywords[4].score | 0.5347769260406494 |
| keywords[4].display_name | Cancer research |
| keywords[5].id | https://openalex.org/keywords/t-cell |
| keywords[5].score | 0.5219666361808777 |
| keywords[5].display_name | T cell |
| keywords[6].id | https://openalex.org/keywords/t-cell-receptor |
| keywords[6].score | 0.4712282419204712 |
| keywords[6].display_name | T-cell receptor |
| keywords[7].id | https://openalex.org/keywords/flow-cytometry |
| keywords[7].score | 0.4605281949043274 |
| keywords[7].display_name | Flow cytometry |
| keywords[8].id | https://openalex.org/keywords/cancer |
| keywords[8].score | 0.42054545879364014 |
| keywords[8].display_name | Cancer |
| keywords[9].id | https://openalex.org/keywords/immunology |
| keywords[9].score | 0.4188340902328491 |
| keywords[9].display_name | Immunology |
| keywords[10].id | https://openalex.org/keywords/immune-system |
| keywords[10].score | 0.39688557386398315 |
| keywords[10].display_name | Immune system |
| keywords[11].id | https://openalex.org/keywords/internal-medicine |
| keywords[11].score | 0.21268999576568604 |
| keywords[11].display_name | Internal medicine |
| keywords[12].id | https://openalex.org/keywords/biology |
| keywords[12].score | 0.20511844754219055 |
| keywords[12].display_name | Biology |
| keywords[13].id | https://openalex.org/keywords/in-vitro |
| keywords[13].score | 0.081968754529953 |
| keywords[13].display_name | In vitro |
| language | en |
| locations[0].id | doi:10.1136/jitc-2021-sitc2021.314 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4363604233 |
| locations[0].source.issn | |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Regular and Young Investigator Award Abstracts |
| locations[0].source.host_organization | |
| locations[0].source.host_organization_name | |
| locations[0].license | |
| locations[0].pdf_url | https://jitc.bmj.com/content/jitc/9/Suppl_2/A338.full.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | proceedings-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Regular and Young Investigator Award Abstracts |
| locations[0].landing_page_url | https://doi.org/10.1136/jitc-2021-sitc2021.314 |
| locations[1].id | pmh:oai:doaj.org/article:c53ad500573d4af6b976c2690ebc76e9 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S4306401280 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[1].source.host_organization | |
| locations[1].source.host_organization_name | |
| locations[1].license | cc-by-sa |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | article |
| locations[1].license_id | https://openalex.org/licenses/cc-by-sa |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021) |
| locations[1].landing_page_url | https://doaj.org/article/c53ad500573d4af6b976c2690ebc76e9 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5069423385 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-4768-4505 |
| authorships[0].author.display_name | Bérengère Salomé |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[0].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[0].institutions[0].id | https://openalex.org/I98704320 |
| authorships[0].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Berengere Salome |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[1].author.id | https://openalex.org/A5010082766 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-3101-0266 |
| authorships[1].author.display_name | John P. Sfakianos |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[1].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[1].institutions[0].id | https://openalex.org/I98704320 |
| authorships[1].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | John Sfakianos |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[2].author.id | https://openalex.org/A5074008441 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-4851-6500 |
| authorships[2].author.display_name | Andrew Charap |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[2].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[2].institutions[0].id | https://openalex.org/I98704320 |
| authorships[2].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Andrew Charap |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[3].author.id | https://openalex.org/A5078522441 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-5813-9473 |
| authorships[3].author.display_name | Adam M. Farkas |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[3].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[3].institutions[0].id | https://openalex.org/I98704320 |
| authorships[3].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Adam Farkas |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[4].author.id | https://openalex.org/A5033712473 |
| authorships[4].author.orcid | https://orcid.org/0009-0002-8331-7996 |
| authorships[4].author.display_name | Daniel Geanon |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[4].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[4].institutions[0].id | https://openalex.org/I98704320 |
| authorships[4].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Daniel Geanon |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[5].author.id | https://openalex.org/A5074382498 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Geoffrey Kelly |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[5].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[5].institutions[0].id | https://openalex.org/I98704320 |
| authorships[5].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Geoffrey Kelly |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[6].author.id | https://openalex.org/A5050468493 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Ronaldo de Real |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[6].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[6].institutions[0].id | https://openalex.org/I98704320 |
| authorships[6].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Ronaldo de Real |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[7].author.id | https://openalex.org/A5100371434 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-1337-1105 |
| authorships[7].author.display_name | Brian Lee |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[7].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[7].institutions[0].id | https://openalex.org/I98704320 |
| authorships[7].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Brian Lee |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[8].author.id | https://openalex.org/A5026912903 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-3075-9977 |
| authorships[8].author.display_name | Kristin G. Beaumont |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[8].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[8].institutions[0].id | https://openalex.org/I98704320 |
| authorships[8].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Kristin Beaumont |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[9].author.id | https://openalex.org/A5007683158 |
| authorships[9].author.orcid | https://orcid.org/0000-0003-2839-0322 |
| authorships[9].author.display_name | Sanjana Shroff |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[9].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[9].institutions[0].id | https://openalex.org/I98704320 |
| authorships[9].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[9].institutions[0].type | education |
| authorships[9].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Sanjana Shroff |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[10].author.id | https://openalex.org/A5102965585 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-3984-502X |
| authorships[10].author.display_name | Ying‐Chih Wang |
| authorships[10].countries | US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[10].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[10].institutions[0].id | https://openalex.org/I98704320 |
| authorships[10].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[10].institutions[0].country_code | US |
| authorships[10].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Ying-Chih Wang |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[11].author.id | https://openalex.org/A5066731530 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Yuanshuo Wang |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[11].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[11].institutions[0].id | https://openalex.org/I98704320 |
| authorships[11].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Yuan-Shuo Wang |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[12].author.id | https://openalex.org/A5100336028 |
| authorships[12].author.orcid | https://orcid.org/0000-0002-4706-2482 |
| authorships[12].author.display_name | Li Wang |
| authorships[12].countries | US |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[12].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[12].institutions[0].id | https://openalex.org/I98704320 |
| authorships[12].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[12].institutions[0].type | education |
| authorships[12].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[12].institutions[0].country_code | US |
| authorships[12].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Li Wang |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[13].author.id | https://openalex.org/A5076788078 |
| authorships[13].author.orcid | https://orcid.org/0000-0001-9267-2426 |
| authorships[13].author.display_name | Robert Sebra |
| authorships[13].countries | US |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[13].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[13].institutions[0].id | https://openalex.org/I98704320 |
| authorships[13].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[13].institutions[0].type | education |
| authorships[13].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[13].institutions[0].country_code | US |
| authorships[13].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Robert Sebra |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[14].author.id | https://openalex.org/A5013801897 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-9230-9501 |
| authorships[14].author.display_name | Alice O. Kamphorst |
| authorships[14].countries | US |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[14].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[14].institutions[0].id | https://openalex.org/I98704320 |
| authorships[14].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[14].institutions[0].type | education |
| authorships[14].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[14].institutions[0].country_code | US |
| authorships[14].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Alice Kamphorst |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[15].author.id | https://openalex.org/A5061606756 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-8718-9373 |
| authorships[15].author.display_name | Karl‐Johan Malmberg |
| authorships[15].countries | NO |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I184942183 |
| authorships[15].affiliations[0].raw_affiliation_string | University of Oslo, Oslo, Norway |
| authorships[15].institutions[0].id | https://openalex.org/I184942183 |
| authorships[15].institutions[0].ror | https://ror.org/01xtthb56 |
| authorships[15].institutions[0].type | education |
| authorships[15].institutions[0].lineage | https://openalex.org/I184942183 |
| authorships[15].institutions[0].country_code | NO |
| authorships[15].institutions[0].display_name | University of Oslo |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Karl-Johan Malmberg |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | University of Oslo, Oslo, Norway |
| authorships[16].author.id | https://openalex.org/A5061015160 |
| authorships[16].author.orcid | https://orcid.org/0000-0003-4103-7566 |
| authorships[16].author.display_name | Emanuela Marcenaro |
| authorships[16].countries | IT |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I83816512 |
| authorships[16].affiliations[0].raw_affiliation_string | Department of Experimental Medicine, Geno, Italy |
| authorships[16].institutions[0].id | https://openalex.org/I83816512 |
| authorships[16].institutions[0].ror | https://ror.org/0107c5v14 |
| authorships[16].institutions[0].type | education |
| authorships[16].institutions[0].lineage | https://openalex.org/I83816512 |
| authorships[16].institutions[0].country_code | IT |
| authorships[16].institutions[0].display_name | University of Genoa |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Emanuela Marcenaro |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Department of Experimental Medicine, Geno, Italy |
| authorships[17].author.id | https://openalex.org/A5102760837 |
| authorships[17].author.orcid | https://orcid.org/0000-0002-6995-5193 |
| authorships[17].author.display_name | Pedro Romero |
| authorships[17].affiliations[0].raw_affiliation_string | Department of Oncology UNIL CHUV, Epalinges, Switzerland |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Pedro Romero |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | Department of Oncology UNIL CHUV, Epalinges, Switzerland |
| authorships[18].author.id | https://openalex.org/A5085845989 |
| authorships[18].author.orcid | https://orcid.org/0000-0001-9280-517X |
| authorships[18].author.display_name | Rachel Brody |
| authorships[18].countries | US |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[18].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[18].institutions[0].id | https://openalex.org/I98704320 |
| authorships[18].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[18].institutions[0].type | education |
| authorships[18].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[18].institutions[0].country_code | US |
| authorships[18].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Rachel Brody |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[19].author.id | https://openalex.org/A5060945949 |
| authorships[19].author.orcid | https://orcid.org/0000-0003-1721-6003 |
| authorships[19].author.display_name | Yuko Yuki |
| authorships[19].countries | US |
| authorships[19].affiliations[0].institution_ids | https://openalex.org/I4210130649 |
| authorships[19].affiliations[0].raw_affiliation_string | Frederick National Laboratory for Cancer Research, Frederick, MD, USA |
| authorships[19].institutions[0].id | https://openalex.org/I4210130649 |
| authorships[19].institutions[0].ror | https://ror.org/03v6m3209 |
| authorships[19].institutions[0].type | facility |
| authorships[19].institutions[0].lineage | https://openalex.org/I1299022934, https://openalex.org/I1299303238, https://openalex.org/I4210130649, https://openalex.org/I4210140884 |
| authorships[19].institutions[0].country_code | US |
| authorships[19].institutions[0].display_name | Frederick National Laboratory for Cancer Research |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | Yuko Yuki |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | Frederick National Laboratory for Cancer Research, Frederick, MD, USA |
| authorships[20].author.id | https://openalex.org/A5007653095 |
| authorships[20].author.orcid | https://orcid.org/0000-0002-0990-3500 |
| authorships[20].author.display_name | Maureen P. Martin |
| authorships[20].countries | US |
| authorships[20].affiliations[0].institution_ids | https://openalex.org/I4210130649 |
| authorships[20].affiliations[0].raw_affiliation_string | Frederick National Laboratory for Cancer Research, Frederick, MD, USA |
| authorships[20].institutions[0].id | https://openalex.org/I4210130649 |
| authorships[20].institutions[0].ror | https://ror.org/03v6m3209 |
| authorships[20].institutions[0].type | facility |
| authorships[20].institutions[0].lineage | https://openalex.org/I1299022934, https://openalex.org/I1299303238, https://openalex.org/I4210130649, https://openalex.org/I4210140884 |
| authorships[20].institutions[0].country_code | US |
| authorships[20].institutions[0].display_name | Frederick National Laboratory for Cancer Research |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | Maureen Martin |
| authorships[20].is_corresponding | False |
| authorships[20].raw_affiliation_strings | Frederick National Laboratory for Cancer Research, Frederick, MD, USA |
| authorships[21].author.id | https://openalex.org/A5015541994 |
| authorships[21].author.orcid | https://orcid.org/0000-0002-2692-2180 |
| authorships[21].author.display_name | Mary Carrington |
| authorships[21].countries | US |
| authorships[21].affiliations[0].institution_ids | https://openalex.org/I4210130649 |
| authorships[21].affiliations[0].raw_affiliation_string | Frederick National Laboratory for Cancer Research, Frederick, MD, USA |
| authorships[21].institutions[0].id | https://openalex.org/I4210130649 |
| authorships[21].institutions[0].ror | https://ror.org/03v6m3209 |
| authorships[21].institutions[0].type | facility |
| authorships[21].institutions[0].lineage | https://openalex.org/I1299022934, https://openalex.org/I1299303238, https://openalex.org/I4210130649, https://openalex.org/I4210140884 |
| authorships[21].institutions[0].country_code | US |
| authorships[21].institutions[0].display_name | Frederick National Laboratory for Cancer Research |
| authorships[21].author_position | middle |
| authorships[21].raw_author_name | Mary Carrington |
| authorships[21].is_corresponding | False |
| authorships[21].raw_affiliation_strings | Frederick National Laboratory for Cancer Research, Frederick, MD, USA |
| authorships[22].author.id | https://openalex.org/A5017441443 |
| authorships[22].author.orcid | https://orcid.org/0009-0007-8648-0410 |
| authorships[22].author.display_name | Reza Mehrazin |
| authorships[22].countries | US |
| authorships[22].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[22].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[22].institutions[0].id | https://openalex.org/I98704320 |
| authorships[22].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[22].institutions[0].type | education |
| authorships[22].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[22].institutions[0].country_code | US |
| authorships[22].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[22].author_position | middle |
| authorships[22].raw_author_name | Reza Mehrazin |
| authorships[22].is_corresponding | False |
| authorships[22].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[23].author.id | https://openalex.org/A5004587560 |
| authorships[23].author.orcid | https://orcid.org/0000-0001-6497-4697 |
| authorships[23].author.display_name | Peter Wiklund |
| authorships[23].countries | US |
| authorships[23].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[23].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[23].institutions[0].id | https://openalex.org/I98704320 |
| authorships[23].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[23].institutions[0].type | education |
| authorships[23].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[23].institutions[0].country_code | US |
| authorships[23].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[23].author_position | middle |
| authorships[23].raw_author_name | Peter Wiklund |
| authorships[23].is_corresponding | False |
| authorships[23].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[24].author.id | https://openalex.org/A5058745924 |
| authorships[24].author.orcid | https://orcid.org/0000-0003-0834-8178 |
| authorships[24].author.display_name | Jun Zhu |
| authorships[24].countries | US |
| authorships[24].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[24].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[24].institutions[0].id | https://openalex.org/I98704320 |
| authorships[24].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[24].institutions[0].type | education |
| authorships[24].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[24].institutions[0].country_code | US |
| authorships[24].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[24].author_position | middle |
| authorships[24].raw_author_name | Jun Zhu |
| authorships[24].is_corresponding | False |
| authorships[24].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[25].author.id | https://openalex.org/A5018275141 |
| authorships[25].author.orcid | https://orcid.org/0000-0001-7655-9378 |
| authorships[25].author.display_name | Matthew D. Galsky |
| authorships[25].countries | US |
| authorships[25].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[25].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[25].institutions[0].id | https://openalex.org/I98704320 |
| authorships[25].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[25].institutions[0].type | education |
| authorships[25].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[25].institutions[0].country_code | US |
| authorships[25].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[25].author_position | middle |
| authorships[25].raw_author_name | Matthew Galsky |
| authorships[25].is_corresponding | False |
| authorships[25].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[26].author.id | https://openalex.org/A5055358847 |
| authorships[26].author.orcid | https://orcid.org/0000-0003-1865-4187 |
| authorships[26].author.display_name | Nina Bhardwaj |
| authorships[26].countries | US |
| authorships[26].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[26].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[26].institutions[0].id | https://openalex.org/I98704320 |
| authorships[26].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[26].institutions[0].type | education |
| authorships[26].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[26].institutions[0].country_code | US |
| authorships[26].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[26].author_position | middle |
| authorships[26].raw_author_name | Nina Bhardwaj |
| authorships[26].is_corresponding | False |
| authorships[26].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[27].author.id | https://openalex.org/A5083361833 |
| authorships[27].author.orcid | https://orcid.org/0000-0003-4602-1440 |
| authorships[27].author.display_name | Amir Horowitz |
| authorships[27].countries | US |
| authorships[27].affiliations[0].institution_ids | https://openalex.org/I98704320 |
| authorships[27].affiliations[0].raw_affiliation_string | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| authorships[27].institutions[0].id | https://openalex.org/I98704320 |
| authorships[27].institutions[0].ror | https://ror.org/04a9tmd77 |
| authorships[27].institutions[0].type | education |
| authorships[27].institutions[0].lineage | https://openalex.org/I1320796813, https://openalex.org/I98704320 |
| authorships[27].institutions[0].country_code | US |
| authorships[27].institutions[0].display_name | Icahn School of Medicine at Mount Sinai |
| authorships[27].author_position | last |
| authorships[27].raw_author_name | Amir Horowitz |
| authorships[27].is_corresponding | False |
| authorships[27].raw_affiliation_strings | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://jitc.bmj.com/content/jitc/9/Suppl_2/A338.full.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | 314 NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11020 |
| primary_topic.field.id | https://openalex.org/fields/24 |
| primary_topic.field.display_name | Immunology and Microbiology |
| primary_topic.score | 0.9991999864578247 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2403 |
| primary_topic.subfield.display_name | Immunology |
| primary_topic.display_name | Immune Cell Function and Interaction |
| related_works | https://openalex.org/W2394822632, https://openalex.org/W1774616393, https://openalex.org/W2048716591, https://openalex.org/W1954489675, https://openalex.org/W2052876854, https://openalex.org/W2137904245, https://openalex.org/W2889245661, https://openalex.org/W1969542161, https://openalex.org/W2116880877, https://openalex.org/W2364115806 |
| cited_by_count | 2 |
| counts_by_year[0].year | 2023 |
| counts_by_year[0].cited_by_count | 1 |
| counts_by_year[1].year | 2021 |
| counts_by_year[1].cited_by_count | 1 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1136/jitc-2021-sitc2021.314 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4363604233 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Regular and Young Investigator Award Abstracts |
| best_oa_location.source.host_organization | |
| best_oa_location.source.host_organization_name | |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://jitc.bmj.com/content/jitc/9/Suppl_2/A338.full.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | proceedings-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Regular and Young Investigator Award Abstracts |
| best_oa_location.landing_page_url | https://doi.org/10.1136/jitc-2021-sitc2021.314 |
| primary_location.id | doi:10.1136/jitc-2021-sitc2021.314 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4363604233 |
| primary_location.source.issn | |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Regular and Young Investigator Award Abstracts |
| primary_location.source.host_organization | |
| primary_location.source.host_organization_name | |
| primary_location.license | |
| primary_location.pdf_url | https://jitc.bmj.com/content/jitc/9/Suppl_2/A338.full.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | proceedings-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Regular and Young Investigator Award Abstracts |
| primary_location.landing_page_url | https://doi.org/10.1136/jitc-2021-sitc2021.314 |
| publication_date | 2021-11-01 |
| publication_year | 2021 |
| referenced_works | https://openalex.org/W3106449294, https://openalex.org/W2902856530, https://openalex.org/W3214625671, https://openalex.org/W2981056570, https://openalex.org/W4211053712 |
| referenced_works_count | 5 |
| abstract_inverted_index.1 | 19 |
| abstract_inverted_index.2 | 54 |
| abstract_inverted_index.3 | 104, 427, 466 |
| abstract_inverted_index.4 | 105 |
| abstract_inverted_index.7 | 603 |
| abstract_inverted_index.A | 69 |
| abstract_inverted_index.I | 193 |
| abstract_inverted_index.J | 597 |
| abstract_inverted_index.T | 63, 85, 118, 130, 143, 176, 239, 258, 277, 295, 304, 319, 345, 365, 392, 549 |
| abstract_inverted_index.a | 6, 13, 42, 57, 187, 210, 261, 348, 372, 381, 539 |
| abstract_inverted_index.8. | 473 |
| abstract_inverted_index.A, | 444, 495, 517, 575 |
| abstract_inverted_index.B, | 497 |
| abstract_inverted_index.C, | 479, 481, 483, 491, 511 |
| abstract_inverted_index.E, | 503, 531, 583 |
| abstract_inverted_index.E. | 535, 589 |
| abstract_inverted_index.G, | 505 |
| abstract_inverted_index.H, | 523 |
| abstract_inverted_index.J, | 407, 485, 515 |
| abstract_inverted_index.L, | 493, 579 |
| abstract_inverted_index.M, | 411, 413, 434, 489, 525 |
| abstract_inverted_index.NK | 66, 88, 551 |
| abstract_inverted_index.O, | 405, 513 |
| abstract_inverted_index.P, | 446, 477, 521, 573 |
| abstract_inverted_index.R, | 438, 499, 519, 529, 581 |
| abstract_inverted_index.S, | 507 |
| abstract_inverted_index.T, | 487, 571 |
| abstract_inverted_index.T. | 448 |
| abstract_inverted_index.US | 30 |
| abstract_inverted_index.V, | 501 |
| abstract_inverted_index.We | 106 |
| abstract_inverted_index.Y, | 527 |
| abstract_inverted_index.Y. | 417 |
| abstract_inverted_index.as | 137, 139 |
| abstract_inverted_index.by | 5, 28, 301, 309, 315, 546 |
| abstract_inverted_index.in | 91, 116, 121, 282, 455 |
| abstract_inverted_index.is | 3, 56, 306, 538 |
| abstract_inverted_index.of | 46, 52, 60, 111, 171, 181, 190, 199, 233, 267, 369, 386, 458 |
| abstract_inverted_index.on | 128, 140, 163, 195, 204, 235, 334 |
| abstract_inverted_index.to | 73, 82, 219, 253, 284, 290, 357, 375, 398 |
| abstract_inverted_index.we | 185, 229, 272 |
| abstract_inverted_index.13; | 426, 556 |
| abstract_inverted_index.175 | 557 |
| abstract_inverted_index.17; | 602 |
| abstract_inverted_index.29. | 564 |
| abstract_inverted_index.AI, | 509 |
| abstract_inverted_index.CD8 | 62, 84, 257, 276, 294, 303, 318, 344, 364, 391 |
| abstract_inverted_index.DF, | 436, 577 |
| abstract_inverted_index.Dis | 422 |
| abstract_inverted_index.Eur | 461 |
| abstract_inverted_index.HLA | 191, 285 |
| abstract_inverted_index.MA, | 409 |
| abstract_inverted_index.MD, | 440 |
| abstract_inverted_index.ME, | 415 |
| abstract_inverted_index.Nat | 420 |
| abstract_inverted_index.Nov | 472, 563 |
| abstract_inverted_index.Our | 378 |
| abstract_inverted_index.RB, | 533 |
| abstract_inverted_index.Rev | 421 |
| abstract_inverted_index.SB, | 442 |
| abstract_inverted_index.SH, | 587 |
| abstract_inverted_index.and | 32, 65, 80, 87, 93, 150, 156, 227, 249, 269, 313, 395, 450, 550 |
| abstract_inverted_index.are | 279, 322 |
| abstract_inverted_index.der | 585 |
| abstract_inverted_index.for | 35, 213, 351, 383, 396, 452 |
| abstract_inverted_index.has | 77 |
| abstract_inverted_index.mAb | 537 |
| abstract_inverted_index.our | 339 |
| abstract_inverted_index.the | 29, 74, 108, 112, 310, 459, 592 |
| abstract_inverted_index.van | 569, 584 |
| abstract_inverted_index.was | 126, 207 |
| abstract_inverted_index.yet | 39 |
| abstract_inverted_index.(NK) | 222 |
| abstract_inverted_index.2017 | 424 |
| abstract_inverted_index.2018 | 554, 562 |
| abstract_inverted_index.2019 | 600 |
| abstract_inverted_index.2020 | 464, 471 |
| abstract_inverted_index.Burg | 586 |
| abstract_inverted_index.CD28 | 247, 370 |
| abstract_inverted_index.CD8+ | 129, 142, 175, 238 |
| abstract_inverted_index.Cell | 553 |
| abstract_inverted_index.Drug | 33 |
| abstract_inverted_index.Epub | 470, 561 |
| abstract_inverted_index.Flow | 153 |
| abstract_inverted_index.Food | 31 |
| abstract_inverted_index.Guia | 506 |
| abstract_inverted_index.Hall | 570 |
| abstract_inverted_index.Ruan | 576 |
| abstract_inverted_index.Urol | 462 |
| abstract_inverted_index.been | 26, 78 |
| abstract_inverted_index.both | 548 |
| abstract_inverted_index.cell | 67, 86, 89, 119, 177, 296, 305, 320, 393 |
| abstract_inverted_index.data | 340, 379 |
| abstract_inverted_index.doi: | 429, 468, 559, 605 |
| abstract_inverted_index.from | 132, 145, 165, 174 |
| abstract_inverted_index.have | 24 |
| abstract_inverted_index.head | 92 |
| abstract_inverted_index.lack | 367 |
| abstract_inverted_index.mass | 225 |
| abstract_inverted_index.neck | 94 |
| abstract_inverted_index.need | 382 |
| abstract_inverted_index.only | 40 |
| abstract_inverted_index.poor | 7 |
| abstract_inverted_index.rate | 45 |
| abstract_inverted_index.role | 110, 212 |
| abstract_inverted_index.that | 231, 274, 342, 354, 389, 542 |
| abstract_inverted_index.them | 356 |
| abstract_inverted_index.upon | 324 |
| abstract_inverted_index.well | 138 |
| abstract_inverted_index.were | 161 |
| abstract_inverted_index.with | 9, 96, 264, 331 |
| abstract_inverted_index.(e.g. | 202 |
| abstract_inverted_index.April | 425 |
| abstract_inverted_index.Borst | 578 |
| abstract_inverted_index.Breso | 500 |
| abstract_inverted_index.Cohen | 532 |
| abstract_inverted_index.CyTOF | 125 |
| abstract_inverted_index.Denis | 478 |
| abstract_inverted_index.HLA-E | 55, 332 |
| abstract_inverted_index.Habif | 504 |
| abstract_inverted_index.Lantz | 512 |
| abstract_inverted_index.Lopez | 484 |
| abstract_inverted_index.Lotan | 416 |
| abstract_inverted_index.Morel | 494, 526 |
| abstract_inverted_index.NKG2A | 75, 234, 325 |
| abstract_inverted_index.Oncol | 463 |
| abstract_inverted_index.PD-1+ | 237, 293 |
| abstract_inverted_index.PMID: | 431, 474, 565, 607 |
| abstract_inverted_index.Rossi | 496 |
| abstract_inverted_index.Sanli | 404 |
| abstract_inverted_index.Using | 224 |
| abstract_inverted_index.cases | 11 |
| abstract_inverted_index.cells | 64, 131, 144, 164, 240, 259, 278, 346, 366 |
| abstract_inverted_index.class | 192, 286 |
| abstract_inverted_index.found | 186, 273 |
| abstract_inverted_index.fresh | 133, 166 |
| abstract_inverted_index.known | 58 |
| abstract_inverted_index.lower | 373 |
| abstract_inverted_index.lymph | 147 |
| abstract_inverted_index.nodes | 148 |
| abstract_inverted_index.novel | 593 |
| abstract_inverted_index.rate. | 18 |
| abstract_inverted_index.their | 291, 400 |
| abstract_inverted_index.tumor | 102, 172, 360 |
| abstract_inverted_index.where | 327 |
| abstract_inverted_index.(n=11) | 149 |
| abstract_inverted_index.(n=13) | 160 |
| abstract_inverted_index.(n=25) | 155 |
| abstract_inverted_index.(n=6), | 136 |
| abstract_inverted_index.(n=8). | 152 |
| abstract_inverted_index.André | 476, 572 |
| abstract_inverted_index.Arnoux | 486 |
| abstract_inverted_index.Bléry | 488 |
| abstract_inverted_index.Bonnet | 502 |
| abstract_inverted_index.Burger | 410 |
| abstract_inverted_index.Cancer | 599 |
| abstract_inverted_index.Cells. | 552 |
| abstract_inverted_index.DNAM-1 | 268, 311 |
| abstract_inverted_index.Dodion | 520 |
| abstract_inverted_index.Galsky | 439 |
| abstract_inverted_index.HLA-E. | 316 |
| abstract_inverted_index.Hannan | 437 |
| abstract_inverted_index.Herbst | 528 |
| abstract_inverted_index.NKG2A+ | 61, 256, 302, 317, 343, 363 |
| abstract_inverted_index.NKG2A- | 292 |
| abstract_inverted_index.NKG2A. | 596 |
| abstract_inverted_index.Necchi | 443 |
| abstract_inverted_index.PMCID: | 567, 609 |
| abstract_inverted_index.Powles | 447 |
| abstract_inverted_index.Remark | 498 |
| abstract_inverted_index.Sharma | 445 |
| abstract_inverted_index.Soulas | 480 |
| abstract_inverted_index.Vivier | 534, 588 |
| abstract_inverted_index.Zerbib | 518, 580 |
| abstract_inverted_index.across | 100 |
| abstract_inverted_index.assess | 390 |
| abstract_inverted_index.cancer | 2, 37 |
| abstract_inverted_index.cells. | 223 |
| abstract_inverted_index.escape | 173 |
| abstract_inverted_index.immune | 594 |
| abstract_inverted_index.killer | 221 |
| abstract_inverted_index.memory | 243 |
| abstract_inverted_index.partly | 307 |
| abstract_inverted_index.proven | 81 |
| abstract_inverted_index.strong | 349 |
| abstract_inverted_index.trials | 99 |
| abstract_inverted_index.tumors | 135, 151, 206, 288 |
| abstract_inverted_index.weaker | 251 |
| abstract_inverted_index.10-year | 15 |
| abstract_inverted_index.:17022. | 428 |
| abstract_inverted_index.Bajorin | 435 |
| abstract_inverted_index.Bladder | 1, 418 |
| abstract_inverted_index.Dobruch | 406 |
| abstract_inverted_index.Fayette | 514 |
| abstract_inverted_index.Knowles | 408 |
| abstract_inverted_index.Lalanne | 508 |
| abstract_inverted_index.Methods | 124 |
| abstract_inverted_index.NK-like | 299 |
| abstract_inverted_index.Nielsen | 414 |
| abstract_inverted_index.October | 601 |
| abstract_inverted_index.Primers | 423 |
| abstract_inverted_index.Results | 169 |
| abstract_inverted_index.Rouanne | 433 |
| abstract_inverted_index.antigen | 182 |
| abstract_inverted_index.binding | 72 |
| abstract_inverted_index.bladder | 36, 122, 134, 167, 205, 335, 359 |
| abstract_inverted_index.cancer, | 95 |
| abstract_inverted_index.cancer. | 123, 419 |
| abstract_inverted_index.current | 387 |
| abstract_inverted_index.display | 347 |
| abstract_inverted_index.enables | 355 |
| abstract_inverted_index.evasion | 361 |
| abstract_inverted_index.include | 179 |
| abstract_inverted_index.ligands | 201 |
| abstract_inverted_index.natural | 220 |
| abstract_inverted_index.ongoing | 97 |
| abstract_inverted_index.pathway | 115, 312 |
| abstract_inverted_index.possess | 260 |
| abstract_inverted_index.restore | 83, 399 |
| abstract_inverted_index.suggest | 380 |
| abstract_inverted_index.thereby | 48 |
| abstract_inverted_index.tumors. | 168, 196, 336 |
| abstract_inverted_index.(1):263. | 604 |
| abstract_inverted_index.34–76% | 14 |
| abstract_inverted_index.December | 555 |
| abstract_inverted_index.Gauthier | 492 |
| abstract_inverted_index.Hoffmann | 510 |
| abstract_inverted_index.Horowitz | 574 |
| abstract_inverted_index.However, | 197, 255 |
| abstract_inverted_index.Williams | 441 |
| abstract_inverted_index.antibody | 71 |
| abstract_inverted_index.approved | 27 |
| abstract_inverted_index.ascribed | 218 |
| abstract_inverted_index.bladder. | 460 |
| abstract_inverted_index.blockade | 22 |
| abstract_inverted_index.capacity | 350 |
| abstract_inverted_index.clinical | 98 |
| abstract_inverted_index.compared | 289 |
| abstract_inverted_index.complete | 43 |
| abstract_inverted_index.enhanced | 265 |
| abstract_inverted_index.expanded | 141 |
| abstract_inverted_index.features | 244 |
| abstract_inverted_index.function | 300 |
| abstract_inverted_index.immunity | 120, 545 |
| abstract_inverted_index.indicate | 341 |
| abstract_inverted_index.mediated | 308 |
| abstract_inverted_index.multiple | 101 |
| abstract_inverted_index.observed | 230 |
| abstract_inverted_index.outcomes | 451 |
| abstract_inverted_index.pathways | 216 |
| abstract_inverted_index.possible | 211 |
| abstract_inverted_index.promotes | 241, 543 |
| abstract_inverted_index.recently | 25 |
| abstract_inverted_index.receptor | 76 |
| abstract_inverted_index.response | 44, 283 |
| abstract_inverted_index.restored | 323 |
| abstract_inverted_index.strongly | 280 |
| abstract_inverted_index.survival | 17 |
| abstract_inverted_index.thorough | 384 |
| abstract_inverted_index.28406148. | 432 |
| abstract_inverted_index.30503213; | 566 |
| abstract_inverted_index.31623687; | 608 |
| abstract_inverted_index.31–37%, | 47 |
| abstract_inverted_index.33177001. | 475 |
| abstract_inverted_index.Bonnafous | 490 |
| abstract_inverted_index.December; | 465 |
| abstract_inverted_index.Ghadially | 522 |
| abstract_inverted_index.Rationale | 449 |
| abstract_inverted_index.achieving | 41 |
| abstract_inverted_index.activated | 281 |
| abstract_inverted_index.advantage | 263 |
| abstract_inverted_index.alongside | 245 |
| abstract_inverted_index.antitumor | 401 |
| abstract_inverted_index.blockade, | 326 |
| abstract_inverted_index.carcinoma | 457 |
| abstract_inverted_index.cytolytic | 270 |
| abstract_inverted_index.cytometry | 154, 226 |
| abstract_inverted_index.developed | 79 |
| abstract_inverted_index.evaluated | 107 |
| abstract_inverted_index.functions | 321 |
| abstract_inverted_index.harboring | 12 |
| abstract_inverted_index.inhibited | 314 |
| abstract_inverted_index.inhibitor | 59, 541 |
| abstract_inverted_index.performed | 127, 162 |
| abstract_inverted_index.potential | 109 |
| abstract_inverted_index.protocols | 388 |
| abstract_inverted_index.reduction | 189 |
| abstract_inverted_index.responses | 90 |
| abstract_inverted_index.retained, | 208 |
| abstract_inverted_index.scRNAseq, | 228 |
| abstract_inverted_index.(scRNAseq) | 159 |
| abstract_inverted_index.Anti-NKG2A | 536 |
| abstract_inverted_index.Background | 0 |
| abstract_inverted_index.Immunother | 598 |
| abstract_inverted_index.Mechanisms | 170 |
| abstract_inverted_index.PD-1/PD-L1 | 21 |
| abstract_inverted_index.References | 403 |
| abstract_inverted_index.activation | 215, 353 |
| abstract_inverted_index.additional | 50 |
| abstract_inverted_index.anti-tumor | 544 |
| abstract_inverted_index.checkpoint | 540, 595 |
| abstract_inverted_index.circumvent | 358 |
| abstract_inverted_index.correlates | 330 |
| abstract_inverted_index.diminished | 246 |
| abstract_inverted_index.efficiency | 328 |
| abstract_inverted_index.exhaustion | 394 |
| abstract_inverted_index.expression | 194, 198, 248, 266, 333, 368 |
| abstract_inverted_index.functions. | 402 |
| abstract_inverted_index.impairment | 180 |
| abstract_inverted_index.indicating | 209 |
| abstract_inverted_index.inhibiting | 591 |
| abstract_inverted_index.inhibiton. | 377 |
| abstract_inverted_index.inhibitory | 114 |
| abstract_inverted_index.mechanisms | 51 |
| abstract_inverted_index.modulating | 117 |
| abstract_inverted_index.monoclonal | 70 |
| abstract_inverted_index.positively | 329 |
| abstract_inverted_index.prognosis, | 8 |
| abstract_inverted_index.responses. | 68 |
| abstract_inverted_index.strategies | 23, 397 |
| abstract_inverted_index.suggesting | 49, 371 |
| abstract_inverted_index.treatment, | 38 |
| abstract_inverted_index.unleashing | 547 |
| abstract_inverted_index.urothelial | 456 |
| abstract_inverted_index.Alemozaffar | 412 |
| abstract_inverted_index.Conclusions | 337 |
| abstract_inverted_index.HLA-E/NKG2A | 113 |
| abstract_inverted_index.I-deficient | 287 |
| abstract_inverted_index.Jure-Kunkel | 524 |
| abstract_inverted_index.NKG2A+PD-1+ | 275 |
| abstract_inverted_index.Neoadjuvant | 20 |
| abstract_inverted_index.PMC6292840. | 568 |
| abstract_inverted_index.PMC6798508. | 610 |
| abstract_inverted_index.acquisition | 232 |
| abstract_inverted_index.mechanisms. | 362 |
| abstract_inverted_index.neoadjuvant | 453 |
| abstract_inverted_index.reappraisal | 385 |
| abstract_inverted_index.recognition | 178 |
| abstract_inverted_index.resistance. | 53 |
| abstract_inverted_index.sensitivity | 252 |
| abstract_inverted_index.significant | 188 |
| abstract_inverted_index.single-cell | 157 |
| abstract_inverted_index.Accordingly, | 184 |
| abstract_inverted_index.CD112,CD155) | 203 |
| abstract_inverted_index.Monalizumab: | 590 |
| abstract_inverted_index.indications. | 103 |
| abstract_inverted_index.Collectively, | 338 |
| abstract_inverted_index.PD-1-mediated | 376 |
| abstract_inverted_index.characterized | 4 |
| abstract_inverted_index.counterparts. | 297 |
| abstract_inverted_index.immunotherapy | 454 |
| abstract_inverted_index.presentation. | 183 |
| abstract_inverted_index.proliferative | 262 |
| abstract_inverted_index.significantly | 250 |
| abstract_inverted_index.traditionally | 217 |
| abstract_inverted_index.tumor-derived | 236 |
| abstract_inverted_index.(6):728–738. | 467 |
| abstract_inverted_index.Administration | 34 |
| abstract_inverted_index.Boyer-Chammard | 516 |
| abstract_inverted_index.RNA-sequencing | 158 |
| abstract_inverted_index.susceptibility | 374 |
| abstract_inverted_index.Bourbon-Caillet | 482 |
| abstract_inverted_index.TCR-independent | 214, 298, 352 |
| abstract_inverted_index.muscle-invasive | 10 |
| abstract_inverted_index.recurrence-free | 16 |
| abstract_inverted_index.tissue-resident | 242 |
| abstract_inverted_index.Narni-Mancinelli | 530, 582 |
| abstract_inverted_index.bladder-draining | 146 |
| abstract_inverted_index.DNAM-1-activating | 200 |
| abstract_inverted_index.CD3/CD28-signaling. | 254 |
| abstract_inverted_index.(7):1731–1743.e13. | 558 |
| abstract_inverted_index.10.1038/nrdp.2017.22. | 430 |
| abstract_inverted_index.machinery.Strikingly, | 271 |
| abstract_inverted_index.10.1016/j.euo.2020.06.009. | 469 |
| abstract_inverted_index.10.1186/s40425-019-0761-3. | 606 |
| abstract_inverted_index.10.1016/j.cell.2018.10.014. | 560 |
| cited_by_percentile_year.max | 94 |
| cited_by_percentile_year.min | 89 |
| countries_distinct_count | 3 |
| institutions_distinct_count | 28 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.6600000262260437 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.48851153 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |